^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Hepatocellular Cancer
    Drug:icaritin (SNG-162) (ER-α 36 modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

    Excerpt:
    ...The central laboratory must receive specimen of tumor tissue (wax block or white slice) at first, and detect the PD-L1of tumor tissues by immunohistochemistry, only positive expression of PD-L1 in immune cells can be enrolled; 5....
    Trial ID:
    NCT03236649
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.

    Published date:
    05/16/2018
    Excerpt:
    Immune dynamic of NLR, IL-6 and baseline PD-L1 expression of immune cells was evaluated, retrospectively...Icaritin has demonstrated its favorable clinical safety and immune-modulation clinical efficacy. The improved OS was implicated in the subgroups of advanced HCC patients including PD-L1-positive immune cell expression.
    DOI:
    10.1200/JCO.2018.36.15_suppl.4077
    Trial ID:
    NCT01972672